Lakefront Biotherapeutics ADR (LKFT)
NASDAQ: LKFTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LKFT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.18B
- P/E (TTM)
- 2.39
- EPS (TTM)
- $13.94
- Dividend yield
- None
- 52-week range
- 25.68 – 36.24
- Day range
- 33.25 – 33.85
- Volume / Avg
- 162.49K / 280.49K
- Beta
- —
- Shares outstanding
- 65.48M
52-week range
LKFT stock today
On Nov 20, LKFT ended the session at $33.31, shedding $0.08 (0.24%), versus the S&P 500's 3.70% decline. Shares are 8.1% below their 52-week high of $36.24, set on Feb 24, 2026 and 29.7% above the 52-week low of $25.68, in the middle of the past year's range. LKFT is up 1.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.6%.
At 2.4x trailing earnings, Lakefront Biotherapeutics trades below the peer-group median of 15.3x.
Summary generated from market data by MetaCap's automated system. Methodology
About Lakefront Biotherapeutics
Company profileLakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Henry O. Gosebruch
- Headquarters
- Mechelen
- Employees
- 196
- IPO year
- 2015
- Website
- lakefrontbio.com
Analyst forecast
ForecastConsensus (6 analysts)
hold
Avg. price target
$30.85-7.39%
- Strong buy 1
- Buy 1
- Hold 3
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
LKFT news
All LKFT news- Galapagos NV Announces Creation of 150,000 Subscription Rights Under New PlanNasdaq
- Lakefront creëert nieuw inschrijvingsrechtenplanGlobeNewswire
- Lakefront Creates New Subscription Right PlanGlobeNewswire
- Lakefront Launches New EUR 50M Share Buyback Following Completion Of Initial ProgramNasdaqLKFT, LEN.B
- Lakefront start nieuw aandeleninkoopprogramma ter waarde van €50 miljoen na voltooiing van initieel aandeleninkoopprogrammaGlobeNewswire
- Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase ProgramGlobeNewswire
- Galapagos NV Reports Nine Months 2026 Financial Results and Announces Second €50 million Share Repurchase ProgramNasdaqLKFT, LEN.B
- Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business UpdateGlobeNewswire
Lakefront Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NAMSNewAmsterdam Pharma Company N.V. | 18.41 | -5.64% | $2.21B | vs LKFT |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs LKFT |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs LKFT |
| RCUSArcus Biosciences Inc. | 15.62 | -1.01% | $2.25B | vs LKFT |
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs LKFT |
| PVLAPalvella Therapeutics Inc. | 142.85 | -2.00% | $2.09B | vs LKFT |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs LKFT |
| AUPHAurinia Pharmaceuticals Inc | 14.70 | -1.28% | $1.97B | vs LKFT |
Indexes, lists and sector
Lakefront Biotherapeutics stock FAQ
What is Lakefront Biotherapeutics's stock price today?
LKFT last traded at $33.31 as of Nov 20, 4:00 PM EST, down 0.24% on the day. Prices are delayed at least 15 minutes.
What is LKFT's P/E ratio?
LKFT trades at a trailing P/E ratio of 2.39, compared with a median of 15.3 for its closest peers.
Who is Lakefront Biotherapeutics's CEO?
Mr. Henry O. Gosebruch is the chief executive officer of Lakefront Biotherapeutics ADR, which has about 196 employees.
What is the LKFT 52-week high?
The 52-week high for LKFT is $36.24 and the 52-week low is $25.68. The stock is currently 8.1% below its high.